Diabetes Medications Market Examined in New TriMark Publications Study Available at MarketPublishers.com
20 May 2016 • by Natalie Aster
LONDON – Amid the escalating diabetes epidemic, a novel sense of urgency has come over the world. Proactive strategies targeted to preventing the disease are being brought into force by multinational health organizations like the World Health Organization (WHO), and also by the public health departments of developing and industrialized nations, and even at the grassroots level where food ingredients regulations are being passed.
The diabetes drugs industry generated USD 35.6 billion in revenue in 2012, and is poised for robust growth in the next few years.
As of 2014, Merck & Company, Inc. accounted for 14.5% of the total market for diabetes medications, and its share is set to decrease over the next five years. These drug products are commonly taken orally, apart from insulin, exenatide, and pramlintide, and liraglutide. Drugs utilized for the treatment of diabetes mellitus are also called oral antihyperglycemics or oral hypoglycemics.
Comprehensive market research study “Diabetes Drugs Survey” elaborated by TriMark Publications analyses the market globally with a focus on the USA.
The report carefully assessed the widely used approaches to treating diabetes that are presently in use, whilst presenting an in-depth evaluation of emerging technologies that are most likely to be used for diabetes treatment in the offing.
The study gives an overview of the demographics and economics of diabetes globally and in the USA; offers an in-depth understanding of the disease. It explores the overall pharma industry and canvasses the anti-diabetes drug market covering its size and growth, recent trends in diabetic drug usage and key factors impacting the marketplace. The report gives a detailed analysis of the non-insulin and insulin anti-diabetes markets, covering key drivers and trends, key players and their shares, products, a drug development pipeline, forecasts, etc. The study looks into the emerging anti-diabetes technologies and products; carefully explores market challenges, trends, and strategic options. Extensive company profiles of 66 major players are included, too.
More reports by the publisher can be found at TriMark page.